5月25日，据CDE官网消息，黑龙江珍宝岛药业股份有限公司、黑龙江羽迪药业有限责任公司联合申请药品“复方芩兰口服液”，获得临床试验默示许可，受理号CYZB2500437。
公示信息显示，药品“复方芩兰口服液”适应症：辛凉解表，清热解毒。用于外感风热引起的发热，咳嗽，咽痛。
黑龙江珍宝岛药业股份有限公司，成立于1996年，位于鸡西市，是一家以从事医药制造业为主的企业。企业注册资本94114.0609万人民币，实缴资本36000万人民币。
通过天眼查大数据分析，黑龙江珍宝岛药业股份有限公司共对外投资了26家企业，参与招投标项目2058次，知识产权方面有商标信息133条，专利信息205条，此外企业还拥有行政许可229个。
主要股东信息显示，黑龙江珍宝岛药业股份有限公司由黑龙江创达集团有限公司持股80%、亳州郡泽方隆股权投资中心（有限合伙）持股20%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.